Marat Fudim1,2, Andrew R Spector3, Maria-Rosa Costanzo4, Sean D Pokorney1,2, Robert J Mentz1,2, Dariusz Jagielski5, Ralph Augostini6, William T Abraham6, Piotr P Ponikowski5,7, Scott W McKane8, Jonathan P Piccini1,2. 1. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. 2. Division of Cardiology, Duke University Medical Center, Durham, North Carolina. 3. Department of Neurology, Duke University Medical Center, Durham, North Carolina. 4. Division of Cardiology, Advocate Heart Institute, Naperville, Illinois. 5. Department of Cardiology, Centre for Heart Disease, 4th Military Hospital, Wroclaw, Poland. 6. Division of Cardiology, Department of Medicine, The Ohio State University, Columbus, Ohio. 7. Department of Cardiology, Medical University, Military Hospital, Wroclaw, Poland. 8. Respicardia, Inc., Minnetonka, Minnesota.
Abstract
STUDY OBJECTIVES: Early evidence with transvenous phrenic nerve stimulation (PNS) demonstrates improved disease severity and quality of life (QOL) in patients with central sleep apnea (CSA). The goal of this analysis is to evaluate the complete prospective experience with PNS in order to better characterize its efficacy and safety, including in patients with concomitant heart failure (HF). METHODS: Using pooled individual data from the pilot (n = 57) and pivotal (n = 151) studies of the remedē System in patients with predominant moderate to severe CSA, we evaluated 12-month safety and 6- and 12-month effectiveness based on polysomnography data, QOL, and cardiac function. RESULTS: Among 208 combined patients (June 2010 to May 2015), a remedē device implant was successful in 197 patients (95%), 50/57 pilot study patients (88%) and 147/151 pivotal trial patients (97%). The pooled cohort included patients with CSA of various etiologies, and 141 (68%) had concomitant HF. PNS reduced apnea-hypopnea index (AHI) at 6 months by a median of -22.6 episodes/h (25th and 75th percentile; -38.6 and -8.4, respectively) (median 58% reduction from baseline, P < .001). Improvement in sleep variables was maintained through 12 months of follow-up. In patients with HF and ejection fraction ≤ 45%, PNS was associated with improvement in systolic function from 27.0% (23.3, 36.0) to 31.1% (24.0, 41.5) at 12 months (P = .003). In the entire cohort, improvement in QOL was concordant with amelioration of sleep measures. CONCLUSIONS: Transvenous PNS significantly improves CSA severity, sleep quality, ventricular function, and QOL regardless of HF status. Improvements, which are independent of patient compliance, are sustained at 1 year and are associated with acceptable safety.
STUDY OBJECTIVES: Early evidence with transvenous phrenic nerve stimulation (PNS) demonstrates improved disease severity and quality of life (QOL) in patients with central sleep apnea (CSA). The goal of this analysis is to evaluate the complete prospective experience with PNS in order to better characterize its efficacy and safety, including in patients with concomitant heart failure (HF). METHODS: Using pooled individual data from the pilot (n = 57) and pivotal (n = 151) studies of the remedē System in patients with predominant moderate to severe CSA, we evaluated 12-month safety and 6- and 12-month effectiveness based on polysomnography data, QOL, and cardiac function. RESULTS: Among 208 combined patients (June 2010 to May 2015), a remedē device implant was successful in 197 patients (95%), 50/57 pilot study patients (88%) and 147/151 pivotal trial patients (97%). The pooled cohort included patients with CSA of various etiologies, and 141 (68%) had concomitant HF. PNS reduced apnea-hypopnea index (AHI) at 6 months by a median of -22.6 episodes/h (25th and 75th percentile; -38.6 and -8.4, respectively) (median 58% reduction from baseline, P < .001). Improvement in sleep variables was maintained through 12 months of follow-up. In patients with HF and ejection fraction ≤ 45%, PNS was associated with improvement in systolic function from 27.0% (23.3, 36.0) to 31.1% (24.0, 41.5) at 12 months (P = .003). In the entire cohort, improvement in QOL was concordant with amelioration of sleep measures. CONCLUSIONS: Transvenous PNS significantly improves CSA severity, sleep quality, ventricular function, and QOL regardless of HF status. Improvements, which are independent of patient compliance, are sustained at 1 year and are associated with acceptable safety.
Authors: Rami Khayat; David Jarjoura; Kyle Porter; Angela Sow; Jacob Wannemacher; Robert Dohar; Adam Pleister; William T Abraham Journal: Eur Heart J Date: 2015-01-29 Impact factor: 29.983
Authors: Maria Rosa Costanzo; Piotr Ponikowski; Shahrokh Javaheri; Ralph Augostini; Lee Goldberg; Richard Holcomb; Andrew Kao; Rami N Khayat; Olaf Oldenburg; Christoph Stellbrink; William T Abraham Journal: Lancet Date: 2016-09-01 Impact factor: 79.321
Authors: Cecilia Linde; William T Abraham; Michael R Gold; Martin St John Sutton; Stefano Ghio; Claude Daubert Journal: J Am Coll Cardiol Date: 2008-11-07 Impact factor: 24.094
Authors: Dariusz Jagielski; Piotr Ponikowski; Ralph Augostini; Adam Kolodziej; Rami Khayat; William T Abraham Journal: Eur J Heart Fail Date: 2016-07-04 Impact factor: 15.534
Authors: Maria Rosa Costanzo; Piotr Ponikowski; Andrew Coats; Shahrokh Javaheri; Ralph Augostini; Lee R Goldberg; Richard Holcomb; Andrew Kao; Rami N Khayat; Olaf Oldenburg; Christoph Stellbrink; Scott McKane; William T Abraham Journal: Eur J Heart Fail Date: 2018-10-10 Impact factor: 15.534
Authors: Ana Jorbenadze; Marat Fudim; Felix Mahfoud; Phillip B Adamson; Tarek Bekfani; Rolf Wachter; Horst Sievert; Piotr P Ponikowski; John G F Cleland; Stefan D Anker Journal: ESC Heart Fail Date: 2021-05-18